Antibody-drug conjugates (ADCs) represent a revolutionary advancement in the fight against cancer. ADCs combine the precision of antibodies with the destructive capability of cytotoxic drugs. By carrying these potent agents directly to tumor sites, ADCs maximize treatment efficacy while limiting harm to healthy organs. This directed approach holds